Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2020 16:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks –– Conference call today at 6 p.m. Eastern Time to...
April 15, 2020 16:58 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

COPENHAGEN, Denmark, April 15, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
April 01, 2020 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

– On track with 2020 corporate milestones – – Top-line data from PaTH Forward phase 2 trial on track for mid-April – – Conference call today at 4:30 p.m. Eastern Time – COPENHAGEN,...
March 25, 2020 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1

COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
February 12, 2020 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Upcoming Investor Presentation in February

COPENHAGEN, Denmark, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
January 12, 2020 19:45 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
January 09, 2020 16:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
November 18, 2019 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

– Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of...
November 14, 2019 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
November 08, 2019 16:02 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentation in November

COPENHAGEN, Denmark, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...